PMID- 35307801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 13
IP  - 5
DP  - 2022 May
TI  - The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving 
      Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
PG  - 847-872
LID - 10.1007/s13300-022-01228-w [doi]
AB  - Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 
      inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering 
      efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their 
      recognition as cardiorenal medicines. While SGLT2is continue to be recommended 
      among the second-line therapies for the treatment of hyperglycaemia, their true 
      value now extends to the prevention of debilitating and costly cardiovascular and 
      renal events for high-risk individuals, with particular benefit shown in reducing 
      major adverse cardiac events and heart failure (HF) and slowing the progression 
      of chronic kidney disease. However, SGLT2i usage is still suboptimal among groups 
      considered to be at greatest risk of cardiorenal complications. The ongoing 
      coronavirus disease 2019 (COVID-19) pandemic has intensified financial pressures 
      on healthcare systems, which may hamper further investment in newer effective 
      medicines. Emerging evidence indicates that glycaemic control should be 
      prioritised for people with T2DM in the era of COVID-19 and practical advice on 
      the use of T2DM medications during periods of acute illness remains important, 
      particularly for healthcare professionals working in primary care who face 
      multiple competing priorities. This article provides the latest update from the 
      Improving Diabetes Steering Committee, including perspectives on the value of 
      SGLT2is as cost-effective therapies within the T2DM treatment paradigm, with 
      particular focus on the latest published evidence relating to the prevention or 
      slowing of cardiorenal complications. The implications for ongoing and future 
      approaches to diabetes care are considered in the light of the continuing 
      coronavirus pandemic, and relevant aspects of international treatment guidelines 
      are highlighted with practical advice on the appropriate use of SGLT2is in 
      commonly occurring T2DM clinical scenarios. The 'SGLT2i Prescribing Tool for T2DM 
      Management', previously published by the Steering Committee, has been updated to 
      reflect the latest evidence and is provided in the Supplementary Materials to 
      help support clinicians delivering T2DM care.
CI  - (c) 2022. The Author(s).
FAU - Wilding, John P H
AU  - Wilding JPH
AUID- ORCID: 0000-0003-2839-8404
AD  - Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and 
      Medical Sciences, Clinical Sciences Centre, University Hospital Aintree, 
      Liverpool, UK. j.p.h.wilding@liverpool.ac.uk.
FAU - Evans, Marc
AU  - Evans M
AD  - University Hospital Llandough, Cardiff, UK.
FAU - Fernando, Kevin
AU  - Fernando K
AD  - North Berwick Health Centre, North Berwick, UK.
FAU - Gorriz, Jose Luis
AU  - Gorriz JL
AD  - University Hospital Clinic, University of Valencia, Valencia, Spain.
FAU - Cebrian, Ana
AU  - Cebrian A
AD  - Spanish Diabetes Association, Catholic University of Murcia, Service Murciano de 
      Salud, Cartagena, Murcia, Spain.
AD  - Centro de Salud Casco Antiguo Cartagena, Murcia, Spain.
AD  - Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 
      30120, Murcia, Spain.
FAU - Diggle, Jane
AU  - Diggle J
AD  - College Lane Surgery, Ackworth, West Yorkshire, UK.
FAU - Hicks, Debbie
AU  - Hicks D
AD  - TREND Diabetes, Enfield, UK.
FAU - James, June
AU  - James J
AD  - University Hospitals of Leicester NHS Trust, Leicester, UK.
FAU - Newland-Jones, Philip
AU  - Newland-Jones P
AD  - University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
FAU - Ali, Amar
AU  - Ali A
AD  - Royal Blackburn Hospital, Lancashire, UK.
FAU - Bain, Stephen
AU  - Bain S
AD  - Swansea University and Diabetes Research Unit, Swansea, UK.
FAU - Da Porto, Andrea
AU  - Da Porto A
AD  - University of Udine, Udine, Italy.
FAU - Patel, Dipesh
AU  - Patel D
AD  - University College London, London, UK.
FAU - Viljoen, Adie
AU  - Viljoen A
AD  - Cambridge University Hospitals NHS Foundation Trust, Stevenage, UK.
FAU - Wheeler, David C
AU  - Wheeler DC
AD  - University College London, London, UK.
FAU - Del Prato, Stefano
AU  - Del Prato S
AD  - University of Pisa, Pisa, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220320
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8934539
OTO - NOTNLM
OT  - Cardiorenal protection
OT  - Cardiovascular disease
OT  - Cardiovascular risk
OT  - Chronic kidney disease
OT  - Diabetic kidney disease
OT  - Heart failure
OT  - Oral glucose-lowering medicines
OT  - Prescribing tools
OT  - SGLT2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2022/03/22 06:00
MHDA- 2022/03/22 06:01
PMCR- 2022/03/20
CRDT- 2022/03/21 05:45
PHST- 2021/12/20 00:00 [received]
PHST- 2022/02/08 00:00 [accepted]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/22 06:01 [medline]
PHST- 2022/03/21 05:45 [entrez]
PHST- 2022/03/20 00:00 [pmc-release]
AID - 10.1007/s13300-022-01228-w [pii]
AID - 1228 [pii]
AID - 10.1007/s13300-022-01228-w [doi]
PST - ppublish
SO  - Diabetes Ther. 2022 May;13(5):847-872. doi: 10.1007/s13300-022-01228-w. Epub 2022 
      Mar 20.